| Literature DB >> 35117183 |
Xue-Zhong Xing1, Hai-Jun Wang1, Shi-Ning Qu1, Chu-Lin Huang1, Hao Wang1, Zhen-Nan Yuan1, Hao Zhang1, Quan-Hui Yang1.
Abstract
BACKGROUND: There were conflicting data regarding the effects of neoadjuvant therapy (NT) on the short-term outcomes of critically ill cancer patients. The aim of this study was to investigate whether NT adversely affect the short-term outcomes of critically ill cancer patients who underwent surgery.Entities:
Keywords: Neoadjuvant therapy (NT); cancer; critically ill
Year: 2020 PMID: 35117183 PMCID: PMC8799168 DOI: 10.21037/tcr.2019.12.78
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Flow chart of the study.
Characteristics of neoadjuvant therapy in critically ill cancer patients before and after propensity scoring matching
| Clinical variables | Before propensity scores matching | After propensity scores matching | |||||
|---|---|---|---|---|---|---|---|
| NT group (n=128) | nNT group (n=737) | P value | NT group (n=118) | nNT group (n=118) | P value | ||
| Age (years) | 60.08±10.15 | 64.70±12.04 | <0.001 | 59.94±10.01 | 60.52±11.35 | 0.680 | |
| Male (%) | 39 (30.5) | 251 (34.1) | 0.676 | 85 (72.0) | 77 (65.3) | 0.262 | |
| Hypertension (%) | 11 (8.6) | 89 (12.1) | 0.427 | 39 (33.1) | 37 (31.4) | 0.781 | |
| Coronary heart disease (%) | 15 (11.7) | 113 (15.3) | 0.255 | 7 (5.9) | 9 (7.6) | 0.605 | |
| Diabetic mellitus (%) | 1 (0.8) | 13 (1.8) | 0.288 | 11 (9.3) | 13 (11.0) | 0.667 | |
| COPD (%) | 39 (30.5) | 251 (34.1) | 0.416 | 0 | 1 (0.8) | 0.316 | |
| BMI (kg/m2) | 24.39±5.22 | 24.03±3.58 | 0.341 | 24.39±5.22 | 24.55±3.78 | 0.780 | |
| AJCC staging (%) | <0.001 | 0.572 | |||||
| Stage 0−II | 40 (31.2) | 451 (61.2) | 34 (28.8) | 38 (32.2) | |||
| Stage III−IV | 88 (68.8) | 286 (38.8) | 84 (71.2) | 80 (67.8) | |||
| Type of ICU admission (%) | 0.010 | 0.166 | |||||
| Planned admission | 77 (60.2) | 527 (71.5) | 74 (62.7) | 84 (71.2) | |||
| Unplanned admission | 51 (39.8) | 210 (28.5) | 44 (37.3) | 34 (28.8) | |||
| SAPS3 score on ICU admission | 41.77±13.35 | 35.03±12.37 | <0.001 | 41.62±13.42 | 33.24±11.35 | <0.001 | |
| SOFA score on ICU admission | 3.60±2.84 | 2.61±2.70 | <0.001 | 3.42±2.55 | 2.58±2.79 | 0.017 | |
| Septic shock (%) | 6 (4.7) | 31 (4.2) | 0.804 | 5 (4.2) | 4 (3.4) | 0.734 | |
| Acute kidney injury (%) | 5 (3.9) | 22 (3.0) | 0.580 | 5 (4.2) | 5 (4.2) | 1.000 | |
| Mechanical ventilation (%) | 67 (52.3) | 268 (36.4) | 0.001 | 59 (50.0) | 49 (41.5) | 0.191 | |
NT, neoadjuvant therapy; nNT, no neoadjuvant therapy; COPD, chronic obstructive pulmonary disease; BMI, body mass index; AJCC, American Joint Committee on Cancer; SAPS 3, simplified acute physiology score; SOFA, sequential organ failure assessment.
Short term outcome of neoadjuvant therapy in critically ill cancer patients before and after propensity scoring matching
| Clinical variables | Before propensity scores matching | After propensity scores matching | |||||
|---|---|---|---|---|---|---|---|
| NT group (n=128) | nNT group (n=737) | P value | NT group (n=118) | nNT group (n=118) | P value | ||
| Duration of mechanical ventilation | 0.94±1.90 | 0.75±1.91 | 0.315 | 0.75±1.32 | 0.93±2.30 | 0.467 | |
| ICU length of stay (d) | 3.12±3.16 | 3.12±3.63 | 0.982 | 3.11±2.94 | 3.28±4.36 | 0.727 | |
| Hospital length of stay (d) | 17.59±9.33 | 16.70±12.24 | 0.438 | 17.93±9.20 | 17.06±15.7 | 0.603 | |
| ICU death (%) | 5 (3.9) | 10 (1.4) | 0.041 | 4 (3.4) | 2 (1.7) | 0.408 | |
| Hospital death (%) | 5 (3.9) | 10 (1.4) | 0.041 | 4 (3.4) | 2 (1.7) | 0.408 | |
NT, neoadjuvant therapy; nNT, no neoadjuvant therapy; ICU, intensive care unit.
Univariable and multivariable logistic analysis of risk factors of ICU death in critically ill cancer patients before propensity scores matching
| Clinical variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| ICU death (n=15) | ICU alive (n=850) | P value | P value | RR (95% CI) | ||
| Age (years) | 60.87±9.02 | 64.00±11.94 | 0.781 | |||
| Male (%) | 9 (60.0) | 565 (66.5) | 0.599 | |||
| Hypertension (%) | 6 (40.0) | 284 (33.4) | 0.592 | |||
| Coronary heart disease (%) | 5 (33.3) | 95 (11.2) | 0.008 | 0.010 | 9.614 (1.731–53.405) | |
| Diabetic mellitus (%) | 0 | 128 (15.1) | 0.103 | |||
| COPD (%) | 0 | 14 (1.6) | 0.616 | |||
| BMI (kg/m2) | 23.63±3.11 | 24.09±3.87 | 0.674 | |||
| AJCC staging (%) | 0.799 | |||||
| Stage 0-II | 9 (60.0) | 482 (56.7) | ||||
| Stage III-IV | 6 (40.0) | 368 (43.3) | ||||
| Neoadjuvant therapy (%) | 5 (33.3) | 123 (14.5) | 0.041 | 0.118 | 3.502 (0.728–16.852) | |
| Type of ICU admission (%) | <0.001 | 0.990 | ||||
| Planned admission | 0 | 604 (71.1) | ||||
| Unplanned admission | 15 (100.0) | 246 (28.9) | ||||
| SAPS3 on ICU admission | 71.20±15.07 | 35.40±11.80 | <0.001 | 0.026 | 1.070 (1.008–1.135) | |
| SOFA on ICU admission | 10.53±3.94 | 2.62±2.51 | <0.001 | 0.031 | 1.289 (1.024–1.622) | |
| Septic shock (%) | 2 (13.3) | 35 (4.1) | 0.080 | |||
| Acute kidney injury (%) | 3 (20.0) | 24 (2.8) | <0.001 | 0.169 | 3.373 (0.597–19.059) | |
| Mechanical ventilation (%) | 15 (100.0) | 320 (37.6) | <0.001 | 0.991 | ||
ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; BMI, body mass index; AJCC, American Joint Committee on Cancer; SAPS 3, simplified acute physiology score; SOFA, sequential organ failure assessment.